Damora Therapeutics, Inc.
DMRANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$210.9M | −$22.3M | −$39.9M | −$61.2M | −$52.2M | −$33.6M |
| Net income | −$209.8M | −$21.4M | −$38.3M | −$61.6M | −$51.8M | −$34.8M |
| Total assets | $260.5M | $17.1M | $38.2M | $73.2M | $122.2M | $171.6M |
| Total liabilities | $20.1M | $1.3M | $5.9M | $11.4M | $5.0M | $6.1M |
| Equity | $240.4M | $15.8M | $32.3M | $61.8M | $117.2M | $165.5M |
| EPS (diluted) | $3.98 | $-18.53 | $-36.08 | $-2.43 | $-2.05 | — |
| Shares out. | 1.3M | 27.1M | 25.7M | 25.3M | 25.3M | 25.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −87.3%
- Return on assets
- −80.5%
- Return on capital (ROCE)
- −87.7%
- Liabilities / assets
- 7.7%
- Debt / equity
- 0.08×
- Book value / share
- $181.78
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 7.04safe
- Accruals / assets
- −78.0%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Jarrett JenniferOfficer — See Remarks | Mar 30, 2026 | Grant | 500,000 | $0.00 |
| Bruno JulianneDirector | Feb 9, 2026 | Option exercise | 129,000 | $0.00 |
| Fairmount Funds Management LlcDirector | Feb 9, 2026 | Option exercise | 5.8M | $0.00 |
| Sattarzadeh SherwinOfficer — Chief Operating Officer | Jan 5, 2026 | Grant | 190,376 | $0.00 |
| Hewes L. BeckerOfficer — Chief Medical Officer | Jan 5, 2026 | Grant | 264,629 | $0.00 |
| Schambye Hans T.Officer — Chief Executive Officer | Jan 2, 2026 | Option exercise | 1,360 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.3M | 3.1 | +8.4% |
| Apr 30, 2026 | 1.2M | 5.5 | +6.7% |
| Apr 15, 2026 | 1.1M | 4.7 | +35.0% |
| Mar 31, 2026 | 827,221 | 2.5 | +93.4% |
| Mar 13, 2026 | 427,713 | 1.9 | +31.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMay 4, 2026
- Changed auditorApr 20, 2026
- Director / officer change · Regulation FD disclosureMar 23, 2026
- Results of operations · Amended charter or bylaws · Regulation FD disclosureMar 10, 2026
- Entered a material agreementFeb 11, 2026
- Director / officer change · Amended charter or bylaws · Other material eventFeb 10, 2026
- Regulation FD disclosureJan 12, 2026
- Unregistered equity sale · Director / officer changeJan 6, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- 10-QMay 12, 2026
- 3May 8, 2026
- 8-KMay 4, 2026
- ARSMay 1, 2026
- DEF 14AApr 29, 2026
- DEFA14AApr 29, 2026
- SCHEDULE 13G/AApr 23, 2026
- SCHEDULE 13G/AApr 23, 2026
- 8-KApr 20, 2026
- 4Apr 1, 2026
- 3Apr 1, 2026
- 4Mar 25, 2026